Silence Therapeutics (SLN) Return on Sales (2021 - 2025)
Historic Return on Sales for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to 131.81%.
- Silence Therapeutics' Return on Sales fell 1056500.0% to 131.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.5%, marking a year-over-year increase of 15800.0%. This contributed to the annual value of 1.05% for FY2024, which is 6500.0% up from last year.
- As of Q3 2025, Silence Therapeutics' Return on Sales stood at 131.81%, which was down 1056500.0% from 122.12% recorded in Q2 2025.
- Over the past 5 years, Silence Therapeutics' Return on Sales peaked at 0.49% during Q4 2024, and registered a low of 3139.31% during Q1 2021.
- Over the past 5 years, Silence Therapeutics' median Return on Sales value was 3.81% (recorded in 2023), while the average stood at 193.73%.
- In the last 5 years, Silence Therapeutics' Return on Sales skyrocketed by 47949700bps in 2021 and then plummeted by -2006400bps in 2025.
- Over the past 5 years, Silence Therapeutics' Return on Sales (Quarter) stood at 0.0% in 2021, then plummeted by -253221284bps to 3.16% in 2022, then tumbled by -126bps to 7.13% in 2023, then skyrocketed by 107bps to 0.49% in 2024, then tumbled by -27213bps to 131.81% in 2025.
- Its Return on Sales stands at 131.81% for Q3 2025, versus 122.12% for Q2 2025 and 200.92% for Q1 2025.